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Abstract
Introduction: Although rare, angioedema has been documented to occur following the
administration of angiotensin-Converting Enzyme Inhibitors. Angiotensin-converting enzyme
inhibitors are the leading cause of drug induced angioedema. Angiotensin-converting enzyme
inhibitors induced angioedema is a class effect that can affect between 0.1% and 0.5% of patients
taking the drug. It is rarely documented in Nigeria. Lisinopril is a commonly prescribed angiotensinconverting enzyme inhibitors-I which is considered to be generally safe and well tolerated. We report
a case of angioedema following the use of lisinopril.
Case presentation: A 52-year-old man, known hypertensive, presented with severe breathlessness
on exertion, paroxysmal nocturnal dyspnoea and bilateral pedal swelling of six weeks duration. There
was no history of allergy or atopy. He was managed with lisinopril 5 mg o.d, frusemide 40 mg daily,
aspirin 150 mg daily and digoxin 0.25 mg daily.
He re-presented at the medical emergency unit of the hospital two days later with swellings involving
the lips and the lower face of 10 hours duration. There was associated difficulty in swallowing but no
stridor or hoarseness of voice. He did not have skin rashes or pruritus. There was no history of
previous similar episodes.
Physical examination revealed a middle aged man with swollen lips and lower part of the face. The
pharynx was oedematous. The respiratory and cardiovascular system examinations revealed features
of hypertensive heart disease in biventricular failure. Clinical assessment of hypertensive heart disease
in failure with Lisinopril induced Angioedema was made. The Naranjo probability scale indicated that
this adverse drug event was probable.
Lisinopril was discontinued. After administration of corticosteroid and antihistamine, a complete
resolution of the patient’s symptoms was achieved. He was discharged to the medical outpatient unit
of the hospital having recovered fully.
Conclusion: This case is presented for the purposes of documentation since it is a rare occurrence
among Nigerians.
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Introduction
Angioedema, which may be hereditary or non-hereditary,
is an intense, usually disfiguring, temporary swelling of a
localized body area involving the skin, mucosa and
subcutaneous tissues. J. L. Milton first described angioedema in 1876 [1]. Quincke in 1882 [2] was the first to
assign the name angioneurotic edema to the disease. The
word ‘neurotic’ was used as part of the name in an attempt
to describe the observed effect of mental stress on
exacerbations of this disease. Areas commonly affected
by angioedema include the face, lips, tongue, pharynx, the
supraglottic area and, uncommonly, the subglottic area
[3]. Angioedema may also involve the hands and feet, as
well as the gastrointestinal mucous membranes and
genitalia [3].
Hereditary angioedema is a rare autosomal dominant
disorder, which is characterized by recurrent attacks of
angioedema resulting from a deficiency of C1 esterase
inhibitor enzyme [4]. The causes of non-hereditary
angioedema are variable and include acquired C1 esterase
inhibitor deficiency, which is a result of an auto-antibody
to C1-INH, or generation of anti-idiotypic antibody to
monoclonal immunoglobulins which occur in various B
cell lymphoproliferative diseases and other malignancies
[5]. Non-hereditary angioedema may also be idiopathic,
or due to an allergic reaction to food, various inhalants, or
immune complex diseases [5]. Angiotensin converting
enzyme inhibitors now present as one of the most
common causes of non-hereditary angioedema, accounting for 25-39% of cases [5]. Angioedema may be caused by
other drugs as well, particularly aspirin and non-steroidal
anti-inflammatory medications (NSAIDs), radio-contrast
media, angiotensin II receptor antagonists, and certain
antibiotics [5]. Several cases of severe angioedema have
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been reported following treatment with fibrinolytic agents
[5] and a possible association with the use of estrogens,
other antihypertensive drugs and psychotropic drugs has
been suggested [5].
ACEI are used widely in the treatment of hypertension,
heart failure, myocardial infarction, renal failure, and
diabetic nephropathy. Over the last several years, the use
of ACEI has increased enormously, and it is currently
estimated that > 40 million people worldwide are
receiving therapy with ACEI, which could lead to a greater
prevalence of angioedema [6]. The relationship between
drug intake and appearance of angioedema is extremely
important in identification and subsequent withdrawal of
the offending medication in drug induced type.
Soon after the development of ACEI, Wilkin et al reported
angioedema and proposed enhanced kinin effects from
inhibition of kininase II as the underlying mechanism [7].
ACEI have long been recognized to cause angioedema,
with reported incidence varying from 0.1% to 1% [8].
Occurrence of angioedema has been reported with the use
of all ACEI and it is considered a class-related side effect.
The incidence of ACEI-related angioedema is about 3
times higher in blacks than in white subjects; 4-fold higher
incidence among patients with a history of drug rash; a
1.5-fold higher incidence in patients older than 65 years;
an almost 2-fold higher incidence in patients with
seasonal allergies. It also has a 14-fold higher risk of
occurrence in the first week of therapy [9].
Inhibition of ACE blocks angiotensin conversion and
reduces catabolism of bradykinin, a potent vasoactive
peptide, which is degraded by ACE [10]. Hence, it has been
speculated, and there is now some experimental evidence,
that ACE inhibitors induce angioedema by increasing
availability of bradykinin [11-13]. About 85% of cases of
angioedema following exposure to ACEI resolve upon
stopping the drug, it has been recommended that this
simple measure, without further assessments, should be
immediately taken in patients who experience angioedema while taking ACE inhibitors [14,15].
This case report is presented for the purposes of documentation since it is a rare occurrence among Nigerians.

Case presentation

Figure 1.

A 52-year-old Nigerian man of the Yoruba ethnic group,
presented with severe breathlessness on exertion, paroxysmal nocturnal dyspnoea and bilateral pedal swelling of
six weeks duration, having been referred from a private
hospital. He was recently diagnosed hypertensive during
consultation at the referring hospital, few weeks prior to
presentation. He had smoked for 13 pack years and also
Page 2 of 4
(page number not for citation purposes)

Cases Journal 2009, 2:7181

http://casesjournal.com/casesjournal/article/view/7181

Figure 2.

consumed alcohol heavily (≥60 g/day) for thirty years.
There was no history of food or drug allergy and no family
history of atopy.
Physical examination revealed an acutely ill looking
middle aged man. He was not pale. There was no
periorbital or facial swelling. There was no significant
peripheral lymphadenopathy. The main findings were in
the cardiovascular system examination. The pulse was 106
beats per minute, regular and normal volume; the blood
pressure was 145/100 mmHg supine. The apex beat was at
the 6th intercostals space, immediately lateral to the midclavicular line. Heart sounds SI, S2 and S3 gallop rhythm
were heard. Chest examination showed few basal crepitations bilaterally. Fundoscopy revealed a grade 2 hypertensive retinopathy. All other systems were essentially
normal. A clinical assessment of Hypertensive Heart
Disease in failure was made. Although an in-patient
management was offered, the patient however decline.
He was managed on an out-patient basis; he was placed on
lisinopril 5 mg daily, frusemide 40 mg daily, aspirin 150 mg
daily and digoxin 0.25 mg daily.
The patient re-presented at the medical emergency unit of
the hospital two days later with swollen lips and lower face
of 10 hours duration. There was associated difficulty in
swallowing but no stridor or hoarseness of his voice. There
was no swelling of any other part of the body. He had
neither skin rashes nor pruritus. There was no previous
history of similar episode of swollen lips. Other aspects of
his medical history did not show any abnormality and
were not significant as to the likely cause of his disease
state. Physical examination revealed a middle aged man
with swollen lips and lower part of the face. The pharynx
was also oedematous. He was not dyspnoeic.

The breath sounds were vesicular and there were no rales.
The pulse rate was 94 beats per minute and respiratory rate
was 20 breaths per minute respectively. His blood pressure
was 140/90 mmHg. All other body system examination
were essentially normal. A clinical assessment of lisinopril
induced angioedema was made. The lisinopril was
immediately discontinued. He was treated with intravenous hydrocortisone 200 mg stat and followed up with
tabs prednisolone 10 mg tds and tabs chlorpheniramine
4 mg tds. He was seen at the outpatient unit two days later
having recovered fully. The Naranjo probability scale
indicated that this adverse drug event was probable.

Discussion
Angioedema is the rapid swelling of the skin, mucosa and
submucosa tissues [1]. It is a potentially life threatening
condition. Most commonly, it occurs on the lips, tongue,
face, hands or feet. Occasionally, the pharynx and larynx
could be involved with patients presenting with respiratory embarrassment. The bowel and the penis could also
be involved. The swelling is pale, non-itchy, but can
be accompanied by urticaria. Symptoms last for one or
two days.
The common form is mediated by allergy, (which could be
to different substances like food, animal danders, extreme
of temperatures, emotional stress and local trauma); the
well defined inherited form known as hereditary angioedema is due to deficiency and abnormal function of
C1 esterase inhibitor.
ACEI are the leading cause of drug induced angioedema [8].
However, it has been reported as a side effect of some other
medications including NSAIDS, Statins, Proton pump
inhibitors, Selective serotonin reuptake inhibitor and
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other anti-depressant [3]. Although, the patient under
discussion was also on aspirin during this period, it is not
likely to have been responsible for his symptoms because
his clinical improvement was sustained despite the fact that
aspirin was not discontinued from his list of medications.

shares from organisations that stand to gain or lose from
the publication of this case, holding patents related to the
case, or any other competing interests that may cause
embarrassment were they to become public after the
publication of the case.

ACEI induced angioedema is a class effect that can affect
between 0.1% and 0.5% of patients taking the drug.
Although life threatening angioedema has a even lower
frequency, fatal ACEI induced angioedema have been
reported. Most episodes of angioedema reported occurred
within the first week of therapy, but there are reports of
angioedema as long as two years after the initiation of
therapy [8]. Lisinopril which is more potent with a longer
duration of action than either captopril or enalapril has
enjoyed regular prescription from physicians and general
practitioners. The frequency of angioedema associated
with lisinopril is reported to be 0.1% [9].
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